• Explore /
  • Poster
  • / Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).

Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).

Abstract Poster

Authors

null

Alison R. Walker

The Ohio State University Wexner Medical Center, Columbus, OH

Alison R. Walker , Juan Miguel Bergua Burgues , Pau Montesinos , Dale Bixby , Naval Guastad Daver , Marina Konopleva , Stephen Patrick Anthony , Fenlai Tan , Yi Chen , Yu Chen , Yue Shen , Patrick William Burke

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT04139434

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS7071)

DOI

10.1200/JCO.2022.40.16_suppl.TPS7071

Abstract #

TPS7071

Poster Bd #

298a

Abstract Disclosures

Similar Posters

First Author: Guillermo Garcia-Manero

First Author: Justin M. Watts

First Author: Justin M. Watts

First Author: Kim Schellekens